136 related articles for article (PubMed ID: 7756648)
1. A four-hour infusion of recombinant hirudin results in long-term inhibition of arterial-type thrombosis in baboons.
Kotzé HF; Lamprecht S; Badenhorst PN
Blood; 1995 Jun; 85(11):3158-63. PubMed ID: 7756648
[TBL] [Abstract][Full Text] [Related]
2. Antithrombotic potency of hirudin is increased in nonhuman primates by fibrin targeting.
Bode C; Hanson SR; Schmedtje JF; Haber E; Mehwald P; Kelly AB; Harker LA; Runge MS
Circulation; 1997 Feb; 95(4):800-4. PubMed ID: 9054733
[TBL] [Abstract][Full Text] [Related]
3. Determination of the dosage of recombinant hirudin to inhibit arterial thrombosis in baboons.
Kotzé HF; Lamprecht S; Van Wyk V; Roodt JP; Badenhorst PN
J Pharm Sci; 2000 May; 89(5):579-85. PubMed ID: 10756323
[TBL] [Abstract][Full Text] [Related]
4. Experimental thrombosis on a collagen coated arterioarterial shunt in rats: a pharmacological model to study antithrombotic agents inhibiting thrombin formation and platelet deposition.
Freund M; Mantz F; Nicolini P; Gachet C; Mulvihill J; Meyer L; Beretz A; Cazenave JP
Thromb Haemost; 1993 May; 69(5):515-21. PubMed ID: 8322274
[TBL] [Abstract][Full Text] [Related]
5. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH
Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009
[TBL] [Abstract][Full Text] [Related]
6. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
[TBL] [Abstract][Full Text] [Related]
7. Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin: comparison with heparin and aspirin.
Meyer BJ; Badimon JJ; Chesebro JH; Fallon JT; Fuster V; Badimon L
Circulation; 1998 Feb; 97(7):681-5. PubMed ID: 9495304
[TBL] [Abstract][Full Text] [Related]
8. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons.
Kelly AB; Marzec UM; Krupski W; Bass A; Cadroy Y; Hanson SR; Harker LA
Blood; 1991 Mar; 77(5):1006-12. PubMed ID: 1995089
[TBL] [Abstract][Full Text] [Related]
9. Transient interruption of arterial thrombosis by inhibition of factor Xa results in long-term antithrombotic effects in baboons.
Kotzé HF; Lamprecht S; Badenhorst PN; Roodt JP; van Wyk V
Thromb Haemost; 1997 Jun; 77(6):1137-42. PubMed ID: 9241746
[TBL] [Abstract][Full Text] [Related]
10. Sustained antithrombotic activity of hirudin after its plasma clearance: comparison with heparin.
Agnelli G; Renga C; Weitz JI; Nenci GG; Hirsh J
Blood; 1992 Aug; 80(4):960-5. PubMed ID: 1498336
[TBL] [Abstract][Full Text] [Related]
11. PLATSAK, a potent antithrombotic and fibrinolytic protein, inhibits arterial and venous thrombosis in a baboon model.
van Zyl WB; Pretorius GH; Lamprecht S; Roodt JP; Kotzé HF
Thromb Res; 2000 Jun; 98(5):435-43. PubMed ID: 10828483
[TBL] [Abstract][Full Text] [Related]
12. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
[TBL] [Abstract][Full Text] [Related]
13. Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis.
Schaffer LW; Davidson JT; Vlasuk GP; Siegl PK
Circulation; 1991 Oct; 84(4):1741-8. PubMed ID: 1833089
[TBL] [Abstract][Full Text] [Related]
14. In vivo inhibition of acute platelet-dependent thrombosis in a baboon model by Bay U3405, a thromboxane A2-receptor antagonist.
Kotzé HF; Lamprecht S; Badenhorst PN; van Wyk V; Roodt JP; Alexander K
Thromb Haemost; 1993 Oct; 70(4):672-5. PubMed ID: 8115994
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological effects of a novel recombinant hirudin, CX-397, in vivo and in vitro: comparison with recombinant hirudin variant-1, heparin, and argatroban.
Komatsu Y; Inoue Y; Goto Y; Fukazawa T; Hayashi H
Thromb Haemost; 1999 Feb; 81(2):250-5. PubMed ID: 10064001
[TBL] [Abstract][Full Text] [Related]
16. Effects of different hirudins and combinations of low doses of hirudin, heparin and acetylsalicylic acid in a rat microcirculatory thrombosis model.
Krupinski K; Breddin HK
Haemostasis; 1991; 21 Suppl 1():88-92. PubMed ID: 1894199
[TBL] [Abstract][Full Text] [Related]
17. Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis.
Heras M; Chesebro JH; Webster MW; Mruk JS; Grill DE; Penny WJ; Bowie EJ; Badimon L; Fuster V
Circulation; 1990 Oct; 82(4):1476-84. PubMed ID: 2401076
[TBL] [Abstract][Full Text] [Related]
18. The effects of recombinant desulphatohirudin on arterial thrombosis in rats.
Talbot MD; Ambler J; Butler KD; Lees CM; Mitchell KA; Peters RF; Tweed MF; Wallis RB
Haemostasis; 1991; 21 Suppl 1():73-9. PubMed ID: 1654294
[TBL] [Abstract][Full Text] [Related]
19. Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin.
Kelly AB; Maraganore JM; Bourdon P; Hanson SR; Harker LA
Proc Natl Acad Sci U S A; 1992 Jul; 89(13):6040-4. PubMed ID: 1385867
[TBL] [Abstract][Full Text] [Related]
20. Lasting safe interruption of endarterectomy thrombosis by transiently infused antithrombin peptide D-Phe-Pro-ArgCH2Cl in baboons.
Lumsden AB; Kelly AB; Schneider PA; Krupski WC; Dodson T; Hanson SR; Harker LA
Blood; 1993 Apr; 81(7):1762-70. PubMed ID: 8461462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
